| Marshall Manor Nursing Home | |
| 3120 North Street, Guntersville, Alabama 35976 | |
| (256) 582-6561 | |
| Name | Marshall Manor Nursing Home |
|---|---|
| Location | 3120 North Street, Guntersville, Alabama |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 91 |
| Occupancy Rate | 62.75% |
| Medicare ID (CCN) | 015378 |
| Legal Business Name | Preferred Health Holdings Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1629065289 |
| Organization Name | PREFERRED HEALTH HOLDINGS LLC |
| Doing Business As | MARSHALL MANOR |
| Address | 3120 North St, Guntersville, AL 35976 |
| Phone Number | 256-582-6561 |
News Archive
Cerus Corporation announced today that INTERCEPT-treated platelet components were found to be effective for patient support following extended six and seven day storage in a clinical study conducted at four sites in Europe. These data further confirm the safety and therapeutic efficacy of platelets treated with the INTERCEPT Blood System, a pathogen inactivation treatment designed to protect against transfusion-transmitted diseases.
New research shows that high school students experience excessive daytime sleepiness (EDS), with most students sleeping fewer than 7 hours per night.
A telestroke service increases the rate of effective tissue plasminogen activator therapy for patients with acute ischemic stroke treated at community hospitals, according to a report in the October issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Kentucky-based Union Springs Pharmaceuticals announced today an agreement with BIOSAFE® of Pittsburgh to market products containing the patented and novel antimicrobial polymer, HM4100. Similar to its flagship product, MyClyns (antimicrobial germ spray), Union Springs Pharmaceuticals will identify the products as MyClyns Antimicrobial Surface Treatments and will be the first company to bring these unique products to the market.
› Verified 2 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Cerus Corporation announced today that INTERCEPT-treated platelet components were found to be effective for patient support following extended six and seven day storage in a clinical study conducted at four sites in Europe. These data further confirm the safety and therapeutic efficacy of platelets treated with the INTERCEPT Blood System, a pathogen inactivation treatment designed to protect against transfusion-transmitted diseases.
New research shows that high school students experience excessive daytime sleepiness (EDS), with most students sleeping fewer than 7 hours per night.
A telestroke service increases the rate of effective tissue plasminogen activator therapy for patients with acute ischemic stroke treated at community hospitals, according to a report in the October issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Kentucky-based Union Springs Pharmaceuticals announced today an agreement with BIOSAFE® of Pittsburgh to market products containing the patented and novel antimicrobial polymer, HM4100. Similar to its flagship product, MyClyns (antimicrobial germ spray), Union Springs Pharmaceuticals will identify the products as MyClyns Antimicrobial Surface Treatments and will be the first company to bring these unique products to the market.
› Verified 2 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 19.91 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 11.47 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 32.88 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.44 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 2.4 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 4.17 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 22.27 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 98.83 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.83 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 36.65 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 31.9 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 6.91 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 98.97 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 75.15 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 95.03 | 82.93 |
News Archive
Cerus Corporation announced today that INTERCEPT-treated platelet components were found to be effective for patient support following extended six and seven day storage in a clinical study conducted at four sites in Europe. These data further confirm the safety and therapeutic efficacy of platelets treated with the INTERCEPT Blood System, a pathogen inactivation treatment designed to protect against transfusion-transmitted diseases.
New research shows that high school students experience excessive daytime sleepiness (EDS), with most students sleeping fewer than 7 hours per night.
A telestroke service increases the rate of effective tissue plasminogen activator therapy for patients with acute ischemic stroke treated at community hospitals, according to a report in the October issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Kentucky-based Union Springs Pharmaceuticals announced today an agreement with BIOSAFE® of Pittsburgh to market products containing the patented and novel antimicrobial polymer, HM4100. Similar to its flagship product, MyClyns (antimicrobial germ spray), Union Springs Pharmaceuticals will identify the products as MyClyns Antimicrobial Surface Treatments and will be the first company to bring these unique products to the market.
› Verified 2 days ago
Marshall Manor Nursing Home Location: 3120 North Street, Guntersville, Alabama 35976 Phone: (256) 582-6561 |